A federal district court in Miami has issued a preliminary injunction in favor of an American biotechnology company that filed a lawsuit against two health care networks for an alleged fraudulent scheme valued in the millions of dollars.

And for lawyers litigating these types of cases, the outcome shows the measures biotechnology companies, such as Gilead Sciences, might have to take to safeguard their drugs and medical products to prevent fraud, and the numerous steps it can take to put a stop to these networks allegedly perpetrating these actions, said Maria D. Garcia, a partner and co-chairwoman of the health care practice at Kozyak Tropin & Throckmorton in Miami who is not involved in this case.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]